Literature DB >> 34035837

A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Jacqueline M Solomon1, Friedemann Paul2, Claudia Chien2, Jiwon Oh1, Dalia L Rotstein3.   

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory disease of the central nervous system marked by relapses often associated with poor recovery and long-term disability. Magnetic resonance imaging (MRI) is recognized as an important tool for timely diagnosis of NMOSD as, in combination with serologic testing, it aids in distinguishing NMOSD from possible mimics. Although the role of MRI for disease monitoring after diagnosis is not as well established, MRI may provide important prognostic information and help differentiate between relapses and pseudorelapses. Increasing evidence of subclinical disease activity and the emergence of newly approved, highly effective immunotherapies for NMOSD adjure us to re-evaluate MRI as a tool to guide optimal treatment selection and escalation throughout the disease course. In this article we review the role of MRI in NMOSD diagnosis, prognostication, disease monitoring, and treatment selection.
© The Author(s), 2021.

Entities:  

Keywords:  MRI; NMOSD; disease activity; prognosis

Year:  2021        PMID: 34035837      PMCID: PMC8111516          DOI: 10.1177/17562864211014389

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  146 in total

1.  Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder.

Authors:  I H Jeong; J Y Choi; S-H Kim; J-W Hyun; A Joung; J Lee; H J Kim
Journal:  Eur J Neurol       Date:  2017-02-24       Impact factor: 6.089

2.  High-risk syndrome for neuromyelitis optica: a descriptive and comparative study.

Authors:  N Collongues; R Marignier; H Zéphir; F Blanc; S Vukusic; O Outteryck; M Fleury; A Ruet; F Borgel; E Thouvenot; T Moreau; G Defer; N Derache; J Pelletier; B Audoin; M Debouverie; P Labauge; O Gout; W Camu; D Brassat; B Brochet; P Vermersch; C Confavreux; J de Seze
Journal:  Mult Scler       Date:  2011-01-14       Impact factor: 6.312

3.  Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.

Authors:  Claudia Chien; Michael Scheel; Tanja Schmitz-Hübsch; Nadja Borisow; Klemens Ruprecht; Judith Bellmann-Strobl; Friedemann Paul; Alexander U Brandt
Journal:  Mult Scler       Date:  2018-11-26       Impact factor: 6.312

4.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

5.  Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.

Authors:  J N Ratchford; M E Quigg; A Conger; T Frohman; E Frohman; L J Balcer; P A Calabresi; D A Kerr
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

6.  Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder.

Authors:  Min Young Lee; Kok Pin Yong; Jae-Won Hyun; Su-Hyun Kim; Sang-Hyun Lee; Ho Jin Kim
Journal:  Neurology       Date:  2020-09-14       Impact factor: 9.910

7.  Discriminating long myelitis of neuromyelitis optica from sarcoidosis.

Authors:  Eoin P Flanagan; Timothy J Kaufmann; Karl N Krecke; Allen J Aksamit; Sean J Pittock; B Mark Keegan; Caterina Giannini; Brian G Weinshenker
Journal:  Ann Neurol       Date:  2016-02-12       Impact factor: 10.422

8.  Abnormal Baseline Brain Activity in Neuromyelitis Optica Patients Without Brain Lesion Detected by Resting-State Functional Magnetic Resonance Imaging.

Authors:  Yi Liu; Hua Xiong; Xiaojiao Li; Dan Zhang; Chao Yang; Jiayi Yu; Ruikun Liao; Bi Zhou; Xianlong Huang; Zhuoyue Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-08       Impact factor: 2.570

9.  Brain abnormalities in neuromyelitis optica spectrum disorder.

Authors:  Woojun Kim; Su-Hyun Kim; So-Young Huh; Ho Jin Kim
Journal:  Mult Scler Int       Date:  2012-12-03

10.  Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study.

Authors:  Nasrin Asgari; Hanne Pernille Bro Skejoe; Soeren Thue Lillevang; Troels Steenstrup; Egon Stenager; Kirsten Ohm Kyvik
Journal:  BMC Neurol       Date:  2013-04-08       Impact factor: 2.474

View more
  5 in total

1.  Contemporary management challenges in seropositive NMOSD.

Authors:  Fiona Costello; Jodie M Burton
Journal:  J Neurol       Date:  2022-07-11       Impact factor: 6.682

2.  COVID-19 Vaccine-A Potential Trigger for MOGAD Transverse Myelitis in a Teenager-A Case Report and a Review of the Literature.

Authors:  Cristina Oana Mărginean; Lorena Elena Meliț; Maria Teodora Cucuiet; Monica Cucuiet; Mihaela Rațiu; Maria Oana Săsăran
Journal:  Children (Basel)       Date:  2022-05-06

3.  Advanced MRI quantification of neuroinflammatory disorders.

Authors:  Russell Ouellette
Journal:  J Neurosci Res       Date:  2022-04-23       Impact factor: 4.433

4.  Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis.

Authors:  Shuwen Deng; Qiang Lei; Wei Lu
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

Review 5.  Clinical and neuroimaging findings in MOGAD-MRI and OCT.

Authors:  Frederik Bartels; Angelo Lu; Frederike Cosima Oertel; Carsten Finke; Friedemann Paul; Claudia Chien
Journal:  Clin Exp Immunol       Date:  2021-07-18       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.